TY - JOUR
T1 - Bioactive Suture with Added Innate Defense Functionality for the Reduction of Bacterial Infection and Inflammation
AU - Puthia, Manoj
AU - Petrlova, Jitka
AU - Petruk, Ganna
AU - Butrym, Marta
AU - Samsudin, Firdaus
AU - Andersson, Madeleine Å
AU - Strömdahl, Ann-Charlotte
AU - Wasserstrom, Sebastian
AU - Hartman, Erik
AU - Kjellström, Sven
AU - Caselli, Lucrezia
AU - Klementieva, Oxana
AU - Bond, Peter J.
AU - Malmsten, Martin
AU - Raina, Deepak
AU - Schmidtchen, Artur
PY - 2023
Y1 - 2023
N2 - Surgical site infections (SSI) are a clinical and economic burden. Suture-associated SSI may develop when bacteria colonize the suture surface and form biofilms that are resistant to antibiotics. Thrombin-derived C-terminal peptide (TCP)-25 is a host defense peptide with a unique dual mode of action that can target both bacteria and the excessive inflammation induced by bacterial products. The peptide demonstrates therapeutic potential in preclinical in vivo wound infection models. In this study, the authors set out to explore whether TCP-25 can provide a new bioactive innate immune feature to hydrophilic polyglactin sutures (Vicryl). Using a combination of biochemical, biophysical, antibacterial, biofilm, and anti-inflammatory assays in vitro, in silico molecular modeling studies, along with experimental infection and inflammation models in mice, a proof-of-concept that TCP-25 can provide Vicryl sutures with a previously undisclosed host defense capacity, that enables targeting of bacteria, biofilms, and the accompanying inflammatory response, is shown.
AB - Surgical site infections (SSI) are a clinical and economic burden. Suture-associated SSI may develop when bacteria colonize the suture surface and form biofilms that are resistant to antibiotics. Thrombin-derived C-terminal peptide (TCP)-25 is a host defense peptide with a unique dual mode of action that can target both bacteria and the excessive inflammation induced by bacterial products. The peptide demonstrates therapeutic potential in preclinical in vivo wound infection models. In this study, the authors set out to explore whether TCP-25 can provide a new bioactive innate immune feature to hydrophilic polyglactin sutures (Vicryl). Using a combination of biochemical, biophysical, antibacterial, biofilm, and anti-inflammatory assays in vitro, in silico molecular modeling studies, along with experimental infection and inflammation models in mice, a proof-of-concept that TCP-25 can provide Vicryl sutures with a previously undisclosed host defense capacity, that enables targeting of bacteria, biofilms, and the accompanying inflammatory response, is shown.
U2 - 10.1002/adhm.202300987
DO - 10.1002/adhm.202300987
M3 - Article
C2 - 37689972
SN - 2192-2659
VL - 12
JO - Advanced healthcare materials
JF - Advanced healthcare materials
IS - 31
ER -